Mannkind

16-18X seems very highly conservative. The market itself will be growing at a good clip rivaling a third of that. I also think many drugs and devices launch slower and increase as post market data is released and market acceptance grows. Remember, MNKD will have extensive trial data to support it's commercialization. I would use 30X ... conservatively for the first 5 years.